Lindsay M Miller1,2, Nancy S Jenny3, Andreea M Rawlings2,4, Alice M Arnold5, Annette L Fitzpatrick6, Oscar L Lopez7, Michelle C Odden2,8. 1. Division of Nephrology-Hypertension, Department of Medicine, University of San Diego, La Jolla. 2. School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis. 3. Department of Pathology and Laboratory Medicine, University of Vermont, Burlington. 4. Kaiser Permanente Center for Health Research, Portland, Oregon. 5. Department of Biostatistics, University of Washington, Seattle. 6. Departments of Family Medicine, Epidemiology, and Global Health, University of Washington, Seattle. 7. Department of Neurology, University of Pittsburgh, Pennsylvania. 8. Department of Health Research and Policy, Stanford University, Stanford, California.
Abstract
BACKGROUND: The importance of systemic inflammation, measured by C-reactive protein, in cognitive decline has been demonstrated; however, the role of vascular inflammation is less understood. Pentraxin 3 (PTX3) is a novel marker of vascular inflammation. METHODS: We followed adults 65 and older, free of cardiovascular disease (CVD) for up to 9 years (n = 1,547) in the Cardiovascular Health Study. We evaluated the relationship between PTX3 and change in cognitive function, measured using the Modified Mini-Mental State Examination (3MSE), and incident cognitive impairment (3MSE < 80). Mediation by CVD events, and effect modification by sex and apolipoprotein E ɛ4 allele (APOE4) were also examined. RESULTS: The average decline in 3MSE was 0.77 points per year. The association between PTX3 and change in 3MSE differed between women and men (p = .02). In the adjusted model, each standard deviation higher in PTX3 was associated with a 0.20 greater decline in 3MSE score per year in women over follow-up (95% CI: -0. 37, -0.03; p = .02), compared to no change in men (β = 0.07; 95% CI: -0.08, 0.22). CVD events had a minor effect on the associations. No effect modification by APOE4 was found, although we observed the association of PTX3 and cognitive impairment in women was attenuated and nonsignificant after adjustment for APOE4. There was a paradoxical protective association between PTX3 and reduced cognitive impairment in men, even after adjustment for APOE4. CONCLUSIONS: We found that vascular inflammation was significantly associated with cognitive decline in older women, but not men.
BACKGROUND: The importance of systemic inflammation, measured by C-reactive protein, in cognitive decline has been demonstrated; however, the role of vascular inflammation is less understood. Pentraxin 3 (PTX3) is a novel marker of vascular inflammation. METHODS: We followed adults 65 and older, free of cardiovascular disease (CVD) for up to 9 years (n = 1,547) in the Cardiovascular Health Study. We evaluated the relationship between PTX3 and change in cognitive function, measured using the Modified Mini-Mental State Examination (3MSE), and incident cognitive impairment (3MSE < 80). Mediation by CVD events, and effect modification by sex and apolipoprotein E ɛ4 allele (APOE4) were also examined. RESULTS: The average decline in 3MSE was 0.77 points per year. The association between PTX3 and change in 3MSE differed between women and men (p = .02). In the adjusted model, each standard deviation higher in PTX3 was associated with a 0.20 greater decline in 3MSE score per year in women over follow-up (95% CI: -0. 37, -0.03; p = .02), compared to no change in men (β = 0.07; 95% CI: -0.08, 0.22). CVD events had a minor effect on the associations. No effect modification by APOE4 was found, although we observed the association of PTX3 and cognitive impairment in women was attenuated and nonsignificant after adjustment for APOE4. There was a paradoxical protective association between PTX3 and reduced cognitive impairment in men, even after adjustment for APOE4. CONCLUSIONS: We found that vascular inflammation was significantly associated with cognitive decline in older women, but not men.
Authors: P P De Deyn; J Goeman; A Vervaet; B Dourcy-Belle-Rose; D Van Dam; E Geerts Journal: Clin Neurol Neurosurg Date: 2011-08-20 Impact factor: 1.876
Authors: James R Hall; April R Wiechmann; Leigh A Johnson; Melissa Edwards; Robert C Barber; A Scott Winter; Meharvan Singh; Sid E O'Bryant Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472
Authors: L Mosconi; R Mistur; R Switalski; M Brys; L Glodzik; K Rich; E Pirraglia; W Tsui; S De Santi; M J de Leon Journal: Neurology Date: 2008-11-12 Impact factor: 9.910
Authors: Gloria C Chi; Annette L Fitzpatrick; Monisha Sharma; Nancy S Jenny; Oscar L Lopez; Steven T DeKosky Journal: J Gerontol A Biol Sci Med Sci Date: 2017-06-01 Impact factor: 6.053